Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
There was a post-hoc analysis of primary prevention of a multicenter prospective randomized controlled study: Assessing the treatment effect in Metabolic Syndrome Without Perceptible diabetes (ATTEMPT), that included 1123 patients with a mean observation of 4 years that had similar clinical and biochemical benefits with a higher dose of atorvastatin (30 mg per day) in 326 patients who had moderately elevated levels of hepatic enzymes and ultrasonographic findings of NAFLD
However, a recent study has shown that a dual GLP-1 and GIP receptor agonist achieves better glycemic control, insulin sensitivity, lipid metabolism, and body weight reduction (14) compared to either treatment alone
Other symptoms to note : Spots may blister over time
Nature Reviews Drug Discovery 24 , 85 (2025) doi: Competing Interests The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies
US$ 22.67
US$ 24.61
US$ 20.61
US$ 27.16
